Nasdaq ardx.

Nov 24, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ... Ardelyx Inc (NASDAQ: ARDX)’s stock price has soared by 1.15 in relation to previous closing price of 4.33. Nevertheless, the company has seen a gain of 16.49% in its stock price over the last five trading days. PennyStocks reported 2023-11-17 that When it comes to finding penny stocks to buy, there are plenty of things […]The latest price target for . Ardelyx (NASDAQ: ARDX) was reported by HC Wainwright & Co. on November 1, 2023.The analyst firm set a price target for $11.00 expecting ARDX to rise to within 12 ...WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...

Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)31 thg 8, 2023 ... The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 8.59 / share. This is an increase of 18.82% from the prior ...

WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended …Dec 18, 2022 · Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ... The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ...

Ardelyx Inc stock price (ARDX) NASDAQ: ARDX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Ardelyx Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

Aug 31, 2023 · Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ...

Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago.According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at …About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...Ardelyx, Inc. (NASDAQ:ARDX) rose 21.9% to $1.39 in pre-market trading after Citigroup raised its price target on the stock $7 to $13. Globus Maritime Limited (NASDAQ:GLBS) ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ...

Join the Nasdaq+ community for more personalized data, exclusive content, and market analysis. Try it today for $4.99/month. Subscribe Now.WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ... View the latest Ardelyx Inc. (ARDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...

WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ...

Ardelyx Inc (NASDAQ:ARDX)’s Major holders. Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. As of Jun 29, 2023, the company held …WALTHAM, Mass., Oct. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.10. 3 Months Ago. -$0.11. Ardelyx Inc. analyst estimates, including ARDX earnings per share estimates and analyst recommendations.Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press ...Price. %Change. 4.380. +1.62%. You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform. Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX options chain data, and a fully built ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...The latest price target for . Ardelyx (NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023.The analyst firm set a price target for 11.00 expecting ARDX to rise to ...

Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...

Mar 6, 2023 · On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ...

Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. Track Ardelyx Inc (ARDX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable ...FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …11 thg 8, 2020 ... Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on ...Ardelyx Inc (NASDAQ:ARDX) is the most popular stock in this table. On the other hand Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS ) is the least popular one with only 8 bullish hedge fund positions.NasdaqGM:ARDX Insider Trading Volume June 12th 2021 Ardelyx is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Find the latest SEC Filings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...Instagram:https://instagram. analysts ratingswww.marketbeat.com analyst ratingshow to add dental insurance to marketplacegoogl target price WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...One thing we could say about the analysts on Ardelyx, Inc. (NASDAQ:ARDX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ... best place to buy optionssana syrian Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... db horton WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ...